In the first quarter, PUMA achieved sales of € 2,076 million, which is in constant currencies on last year's level, despite a challenging environment. Our adjusted operating profit came in broadly in line with our expectations at € 76 million. We introduced exciting new products such as the Speedcat Ballet and our first ever collection with Hyrox to include performance footwear and apparel. We also launched our biggest brand campaign to date “Go Wild”. PUMA remains committed to executing the nextlevel cost efficiency program which is progressing as planned. For 2025, we expect currency adjusted sales to grow in the low- to mid-single-digit percentage range and an adjusted EBIT in the range of € 520 million to € 600 million. Find out more below👇
Nice work, PUMA. Keep performing, and we’ll keep turning heads in the all-red Enzos. #RedShoeCrew
PUMA's holding strong 👏 Excited to see the impact of the new Hyrox collection and the “Go Wild” campaign!
Steady performance in a tough market speaks volumes. PUMA’s focus on innovation, from the Speedcat Ballet to the Hyrox collection, combined with bold campaigns like ‘Go Wild,’ shows how brand agility and efficiency can go hand-in-hand. Looking forward to seeing how 2025 unfolds!
Great job, Puma Cats! cant wait to see what MOSTRO and H-STREET bring to the table. The GO WILD campaign is looking awesome, and recent collabs like HYROX, Off-White, Balenciaga, Harry Potter etc. are really leveling things up. PUMA’s on track to be the most wanted brand out there 🫡 #GOWILD
PUMA continues to demonstrate resilience, balancing exciting product launches with strategic cost efficiency. The ‘Go Wild’ campaign is a bold step, and with a solid outlook for 2025, it’s clear PUMA is paving the way for sustainable growth in a challenging landscape.
We have shared PUMA Group
Medical Director | Obagi Medical Products | Clinical Strategy & Innovation in Aesthetic Dermatology
3w👏